These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12569290)

  • 21. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma.
    Bajetta E; Rimassa L; Carnaghi C; Del Vecchio M; Celio L; Cassata A
    Tumori; 1998; 84(1):48-51. PubMed ID: 9619714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study.
    Jelić S; Babović N; Stamatović L; Kreacić M; Matković S; Popov I
    Med Oncol; 2001; 18(3):189-95. PubMed ID: 11917943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
    Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
    Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A
    Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
    Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
    Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
    Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
    J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    Stein ME; Bernstein Z; Tsalic M; Drumea K; Steiner M; Sklar Z; Haim N
    Am J Clin Oncol; 2002 Oct; 25(5):460-3. PubMed ID: 12393984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dacarbazine and interferon alpha for stage IV malignant melanoma.
    Tamm I; Grimme H; Bergen E; Simon JC; Schöpf E; Mertelsmann R; Lindemann A; Brennscheidt U
    Oncology; 1997; 54(4):270-4. PubMed ID: 9216849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
    Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.